ACTUATE THERAPEUTICS INC
ACTUNASDAQTrading Snapshot
- Day Range
- $0.68 – $0.69
- 52-Week Range
- $0.60 – $8.49
- Volume
- $5.46B
- Avg Volume
- $5.03B
- Shares Outstanding
- 23.9M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $706,548
- P/E Ratio
- -0.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.86
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.1%
Why Investors Own ACTU
- ✓High-growth profile — revenue up +13.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ACTUATE THERAPEUTICS INC
ACTU
StockOtter · stockotter.spaceAbout ACTUATE THERAPEUTICS INC
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for th
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.